You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Immunotherapy in Special Populations With Non-Small Cell Lung Cancer: What Would the Oncologist Do?

  • Authors: Jared Weiss, MD; Ibiayi Dagogo-Jack, MD​; Heather Wakelee, MD​; Charu Aggarwal, MD, MPH
  • CME / ABIM MOC Released: 10/27/2023
  • Valid for credit through: 10/27/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, pulmonologists, and other clinicians who treat patients with NSCLC.

The goal of this activity is for learners to be better able to utilize strategies that facilitate the safe and effective use of immunotherapy in patients with NSCLC as clinically appropriate.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical trial data evaluating immunotherapy use in special populations with NSCLC
  • Have greater competence related to
    • Identifying patients of a special population with NSCLC who may be considered for treatment with immunotherapy
    • Developing customized care plans that include immunotherapy for patients of a special population with NSCLC as clinically appropriate
  • Demonstrate greater confidence in their ability to
    • Recognize factors that may affect the safety and efficacy of immunotherapy in special populations with NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Jared Weiss, MD

    Professor of Medicine
    Division of Oncology
    Lineberger Comprehensive Cancer Center
    University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina

    Disclosures

    Jared Weiss, MD, has the following relevant financial relationships:
    Consultant or advisor for: BeiGene Co., Ltd; EMD Serono, Inc.; Genmab; Gilead Sciences, Inc.; Merck & Co., Inc.; Nanobiotix; Regeneron Pharmaceuticals, Inc. (former); Sanofi; Vesselon
    Research funding from: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Loxo Oncology/Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; PDS Biotech; SDP Pharma LTD
    Stock options from: Vesselon
    Owns stock (publicly traded) in: Achilles Therapeutics; Alnylam Pharmaceuticals; Lyell Immunopharma Inc.; Merus; Nektar Therapeutics; Nuvalent, Inc.; Vertex Pharmaceuticals

  • Ibiayi Dagogo-Jack, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Ibiayi Dagogo-Jack, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; BostonGene Corporation; Bristol Myers Squibb Company; Catalyst Pharmaceutical Partners, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merus; Novocure; Pfizer, Inc.; Roche; Sanofi-Genzyme Corporation; Syros Pharmaceuticals, Inc.; Thermo Fisher Scientific; Xcovery
    Research funding from: Array BioPharma; Genentech, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Tango Therapeutics; Vivace Therapeutics, Inc.

  • Heather Wakelee, MD

    Professor of Medicine
    Chief, Division of Oncology
    Stanford University School of Medicine
    Deputy Director
    Stanford Cancer Institute
    Stanford, California

    Disclosures

    Heather Wakelee, MD, has the following relevant financial relationships:
    Consultant or advisor for: Genentech, Inc. (uncompensated, ongoing); Merck & Co., Inc. (uncompensated, ongoing); Mirati Therapeutics, Inc. (former); Roche (uncompensated, ongoing)
    Research funding from: AstraZeneca; Bayer HealthCare; Bristol Myers Squibb Company; Clovis Oncology; Genentech/Roche; Helsinn Therapeutics, Inc; Merck & Co., Inc.; SeaGen Inc.; Xcovery

  • Charu Aggarwal, MD, MPH

    Leslye M. Heisler Associate Professor of Medicine  ​
    Section Chief, Thoracic and Head and Neck Cancer ​
    Associate Director, Penn Center for Cancer Care Innovation  ​
    Physician Leader, Airways Malignancies Clinical Research ​
    University of Pennsylvania  ​
    Philadelphia, Pennsylvania 

    Disclosures

    Charu Aggarwal, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals; Lilly; Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Shionogi & Co., Ltd.; Turning Point Therapeutics, Inc.
    Research funding from: AstraZeneca/MedImmune Inc.; Genentech, Inc.; Incyte Corporation; MacroGenics, Inc.; Merck Sharp & Dohme; Roche

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Immunotherapy in Special Populations With Non-Small Cell Lung Cancer: What Would the Oncologist Do?

Authors: Jared Weiss, MD; Ibiayi Dagogo-Jack, MD​; Heather Wakelee, MD​; Charu Aggarwal, MD, MPHFaculty and Disclosures

CME / ABIM MOC Released: 10/27/2023

Valid for credit through: 10/27/2024, 11:59 PM EST

processing....

Contents of This Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Patients With Poor Performance Status (ECOG ≥ 2) or Increased Age

Should immunotherapy be administered to elderly patients with NSCLC or those with poor performance status?
Jared Weiss, MD; Ibiayi Dagogo-Jack, MD

Patients With Untreated Brain Metastases

Do patients with NSCLC and untreated brain metastases respond to treatment with immunotherapy?
Jared Weiss, MD; Heather Wakelee, MD

Patients With Kidney or Hepatic Impairment

Are you administering immunotherapy safely to patients with NSCLC and kidney and/or hepatic impairment?
Jared Weiss, MD; Charu Aggarwal, MD, MPH

Patients With Controlled HIV or an Autoimmune Disorder

Can patients with controlled HIV or autoimmune disorders receive immunotherapy for NSCLC?
Jared Weiss, MD; Heather Wakelee, MD

Patients With Unique Histology, Stage, or Other Complicating Factors

Learn about unique criteria that may affect the administration of immunotherapy in patients with NSCLC.
Jared Weiss, MD; Charu Aggarwal, MD, MPH
 

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print